results
Jump to
16 Results Found
  • Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key Apr 12, 2018 05:53 PM IST

    Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

    Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

  • Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key Jan 18, 2018 08:36 AM IST

    Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

    As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

  • Australia biz expanded; rebounded strongly in India & EMs: Strides Shasun Oct 31, 2017 04:11 PM IST

    Australia biz expanded; rebounded strongly in India & EMs: Strides Shasun

    In an interview to CNBC-TV18, Shashank Sinha, Managing Director of Strides Shasun spoke about the results and his outlook for the company.

  • Border tax counter productive for US, may never happen: Strides Feb 07, 2017 02:30 PM IST

    Border tax counter productive for US, may never happen: Strides

    Going forward, the pharma company is going to to focus on its B2C business and the high cash generating verticals, he says.

  • Q2 has been a comeback quarter for us in EMs: Stides Shasun Oct 28, 2016 05:16 PM IST

    Q2 has been a comeback quarter for us in EMs: Stides Shasun

    In an interview to CNBC-TV18, Shashank Sinha, Group CEO of Strides Shasun spoke about the results and his outlook for the company.

  • API biz turnaround likely in 6-8 months: Strides Shasun Aug 18, 2016 09:58 AM IST

    API biz turnaround likely in 6-8 months: Strides Shasun

    In an interview to CNBC-TV18, Arun Kumar, Executive VC and MD of Strides Shasun said the company may sell off its API unit after enhancing its value.

  • Strides Shasun Q1 numbers 10% below estimate: Nirmal Bang Aug 17, 2016 03:50 PM IST

    Strides Shasun Q1 numbers 10% below estimate: Nirmal Bang

    Strides Shasun for the first quarter reported net profit at Rs 41.79 crore and total income stood at Rs 870 crore versus Rs 955 crore quarter on quarter.

  • What to expect from Strides Shasun Q1? Aug 17, 2016 01:24 PM IST

    What to expect from Strides Shasun Q1?

    CNBC-TV18‘s Ekta Batra talks about what to expect from Strides Shasun‘s numbers today.

  • Strides Shasun Q1 PAT seen down by 8.9% at Rs 87.6 cr: Religare Jul 16, 2016 01:09 PM IST

    Strides Shasun Q1 PAT seen down by 8.9% at Rs 87.6 cr: Religare

    Sales are expected to decrease by 4.7 percent Q-o-Q (up 58.3 percent Y-o-Y) to Rs 955.0 crore, according to Religare Research.

  • See margin growing, Australian biz picking up: Strides Shasun May 16, 2016 04:14 PM IST

    See margin growing, Australian biz picking up: Strides Shasun

    Third quarter performance was hit due to floods in Chennai but there has been a strong pullback in the last quarter, he said, adding growth in business from regulated markets like Australia and the US have helped, said Arun Kumar, Executive VC & MD at Strides Shasun.

  • Aim to grow biz at 20-25% CAGR: Strides Shasun Feb 09, 2016 09:40 AM IST

    Aim to grow biz at 20-25% CAGR: Strides Shasun

    The growth trajectory is very strong going forward and the company has all the necessary engines to grow the business at 20-25 percent CAGR, said Arun Kumar, MD, Strides Shasun.

  • See pharma sector's Q3 topline to grow 22%: Motilal Oswal Jan 12, 2013 11:54 AM IST

    See pharma sector's Q3 topline to grow 22%: Motilal Oswal

    Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

  • Strides Arcolab bets on Agila to drive growth in FY13 Apr 26, 2012 04:05 PM IST

    Strides Arcolab bets on Agila to drive growth in FY13

    Group CFO of Strides Arcolab TS Rangan tells CNBC-TV18 that the company is betting on Agila to drive growth in FY13.

  • Stride Arcolab targets Rs 2200cr revenue in 2011 Apr 25, 2011 04:43 PM IST

    Stride Arcolab targets Rs 2200cr revenue in 2011

    Stride Arcolab has declared its first quarter results. The company's Q1 consolidated net profit was up 2.26% at Rs 40.7 crore versus Rs 39.8 crore. For 2011, he says, “A median EBITDA of 21% is the one we are looking at the increased sales of Rs 2,200 crore.”

  • Strides Arcolab Mar qtr PAT seen up at Rs 38.6 cr: MOST Apr 15, 2011 12:16 PM IST

    Strides Arcolab Mar qtr PAT seen up at Rs 38.6 cr: MOST

    Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Strides Arcolab March quarter sales are expected to go up by 28.3% at Rs 479.1 crore, year-on-year, (YoY) basis.

  • Business to grow Rs 1000cr in FY11: Stride Arcolab Feb 24, 2011 06:41 PM IST

    Business to grow Rs 1000cr in FY11: Stride Arcolab

    Stride Arcolab announced it Q3 results for FY11. The company reported a consolidated net profit of Rs 122.4 crore for the year ended 2010 as against Rs 109.7 crore in previous year.

Sections